Advertisement

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Issues in Oncology
Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Peter Clark, MA, MD, FRCP: A Payer Perspective

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Opening Session Panel Discussion

Advertisement

Advertisement




Jul
08
Today In Oncology
Preclinical Leukemia Chip Platform Improves Evaluation of CAR T-Cell Therapies
Addition of Glofitamab to R-CHOP or Pola-R-CHP  in Younger Patients With High-Risk LBCL
Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable HCC
Survey Finds Confusion Over Mammogram Guidelines
Survival Disparities Rise in Patients With Advanced Cancer Depending on Whether They Have Insurance to Cover Immune Checkpoint Inhibitors
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo